Scientific Reports · 2015 · 12 citations · 38 references
MedicineMolecular GeneticsOncologyBreast OncologyCancer GeneticsMolecular OncologyBreast Cancer OncologyCancer Molecular DiagnosticsCancer Molecular PathologyCancer Survival AnalysisMolecular Tumor ProfilingBreast Cancer Molecular SubtypesBreast Cancer PrognosisGenetic Prognostic MarkersMolecular Subtype PredictionMolecular TaxonomyMutation-based PrognosticationRelapse-free SurvivalTp53 Mutations
IHC4 and PAM50 assays have been shown to provide additional prognostic information for patients with early breast cancer. We evaluated whether incorporating TP53 mutation analysis can further enhance their prognostic accuracy. We examined TP53 mutation and the IHC4 score in tumors of 605 patients diagnosed with stage I-III breast cancer at National Taiwan University Hospital (the NTUH cohort). We obtained information regarding TP53 mutation and PAM50 subtypes in 699 tumors from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort. We found that TP53 mutation was significantly associated with high-risk IHC4 group and with luminal B, HER2-enriched, and basal-like subtypes. Despite the strong associations, TP53 mutation independently predicted shorter relapse-free survival (hazard ratio [HR] = 1.63, P = 0.007) in the NTUH cohort and shorter breast cancer-specific survival (HR = 2.35, P = <0.001) in the METABRIC cohort. TP53 mutational analysis added significant prognostic information in addition to the IHC4 score (∆ LR-χ(2) = 8.61, P = 0.002) in the NTUH cohort and the PAM50 subtypes (∆ LR-χ(2) = 18.9, P = <0.001) in the METABRIC cohort. We conclude that incorporating TP53 mutation analysis can enhance the prognostic accuracy of the IHC4 and PAM50 assays.
38
Comprehensive molecular portraits of human breast tumours
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer et al. · New England Journal of Medicine · 2002 · 6.5K citations · Full text
Medicine, Bioinformatics, Oncology +17
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis, Sohrab P. Shah, Suet‐Feung Chin et al. · Nature · 2012 · 6.4K citations · Full text
Life Sciences, Genetics, Oncology +14
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine · 2004 · 6.4K citations · Full text
Medicine, Oncology, Breast Oncology +12